Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP.

BMC Cancer. 2012 Dec 5;12:580. doi: 10.1186/1471-2407-12-580. Review.

PMID:
23217146
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.

Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT.

J Thorac Oncol. 2011 Apr;6(4):824-33. doi: 10.1097/JTO.0b013e3182037b76. Review.

PMID:
21173711
[PubMed - indexed for MEDLINE]
3.

Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Yasumoto K, Hanagiri T, Takenoyama M.

Gen Thorac Cardiovasc Surg. 2009 Sep;57(9):449-57. doi: 10.1007/s11748-008-0433-6. Epub 2009 Sep 13. Review.

PMID:
19756930
[PubMed - indexed for MEDLINE]
4.

Immune modulation as a therapeutic strategy for non-small-cell lung cancer.

Holt GE, Disis ML.

Clin Lung Cancer. 2008 Feb;9 Suppl 1:S13-9. Review.

PMID:
18540530
[PubMed - indexed for MEDLINE]
5.

Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.

Kakimi K, Nakajima J, Wada H.

Lung Cancer. 2009 Jul;65(1):1-8. doi: 10.1016/j.lungcan.2008.10.018. Epub 2008 Dec 4. Review.

PMID:
19062127
[PubMed - indexed for MEDLINE]
6.

Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).

McCarthy F, Roshani R, Steele J, Hagemann T.

J Leukoc Biol. 2013 Dec;94(6):1201-6. doi: 10.1189/jlb.0313121. Epub 2013 May 21. Review.

PMID:
23695306
[PubMed - indexed for MEDLINE]
Free Article
7.

Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.

Shepherd FA, Douillard JY, Blumenschein GR Jr.

J Thorac Oncol. 2011 Oct;6(10):1763-73. doi: 10.1097/JTO.0b013e31822e28fc. Review. Erratum in: J Thorac Oncol. 2012 Jan;7(1):266.

PMID:
21876456
[PubMed - indexed for MEDLINE]
8.

The immune microenvironments of lung and intraocular tumors.

Sautès-Fridman C, Dieu-Nosjean MC, Damotte D, Fisson S, Fridman WH.

Bull Cancer. 2011 Jun;98(6):58-61. doi: 10.1684/bdc.2011.1374.

PMID:
21616749
[PubMed - indexed for MEDLINE]
9.

Modulation of tumor-infiltrating lymphocyte cytolytic activity against human non-small cell lung cancer.

Ortegel JW, Staren ED, Faber LP, Warren WH, Braun DP.

Lung Cancer. 2002 Apr;36(1):17-25.

PMID:
11891029
[PubMed - indexed for MEDLINE]
10.

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

Reck M.

Ann Oncol. 2012 Sep;23 Suppl 8:viii28-34. doi: 10.1093/annonc/mds260. Review.

PMID:
22918925
[PubMed - indexed for MEDLINE]
Free Article
11.

Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.

Van den Heuvel MM, Burgers SA, van Zandwijk N.

Clin Lung Cancer. 2009 Mar;10(2):99-105. doi: 10.3816/CLC.2009.n.012. Review.

PMID:
19362952
[PubMed - indexed for MEDLINE]
12.

TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B.

PLoS One. 2012;7(2):e30676. doi: 10.1371/journal.pone.0030676. Epub 2012 Feb 17.

PMID:
22363469
[PubMed - indexed for MEDLINE]
Free PMC Article
13.
14.

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Kelly RJ, Gulley JL, Giaccone G.

Clin Lung Cancer. 2010 Jul 1;11(4):228-37. doi: 10.3816/CLC.2010.n.029. Review.

PMID:
20630824
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT.

Clin Cancer Res. 2008 Aug 15;14(16):5220-7. doi: 10.1158/1078-0432.CCR-08-0133.

PMID:
18698040
[PubMed - indexed for MEDLINE]
Free Article
16.

Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes.

Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A, Mohanakumar T.

Lung Cancer. 2005 Jan;47(1):17-29.

PMID:
15603851
[PubMed - indexed for MEDLINE]
17.

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.

Cancer Res. 2001 Jun 15;61(12):4766-72.

PMID:
11406550
[PubMed - indexed for MEDLINE]
Free Article
18.

Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.

Zheng YW, Li RM, Zhang XW, Ren XB.

Cancer Invest. 2013 Mar;31(3):197-205. doi: 10.3109/07357907.2013.775294. Review.

PMID:
23477587
[PubMed - indexed for MEDLINE]
19.

Prognostic immune markers in non-small cell lung cancer.

Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS.

Clin Cancer Res. 2011 Aug 15;17(16):5247-56. doi: 10.1158/1078-0432.CCR-10-2805. Epub 2011 Jun 9. Review.

PMID:
21659461
[PubMed - indexed for MEDLINE]
Free Article
20.

[Lung cancer. Molecular pathology and personalized therapy].

Schultheis A, Wolf J, Büttner R.

Internist (Berl). 2013 Feb;54(2):179-80, 182-7. doi: 10.1007/s00108-012-3151-1. German.

PMID:
23371257
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk